查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2008683

陰道炎治療市場：2026-2032年全球市場預測（依治療方法、產品類型、給藥途徑、通路及最終用戶細分市場分類）

Vaginitis Therapeutics Market by Treatment Type, Product Type, Route Of Administration, Distribution Channel, End User Demographics - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，陰道炎治療市場價值將達到 30 億美元，到 2026 年將成長至 32.6 億美元，到 2032 年將達到 56.9 億美元，複合年成長率為 9.55%。

主要市場統計數據
基準年 2025 30億美元
預計年份：2026年 32.6億美元
預測年份 2032 56.9億美元
複合年成長率 (%) 9.55%

這是一份簡潔而有力的陰道炎治療概述，清楚地闡述了相關人員。

由於陰道炎涉及廣泛的臨床需求、診斷的複雜性以及不斷變化的患者偏好，因此它一直是臨床醫生、保險公司和產品開發人員的焦點。以下引言概述了醫療保健和生命科學相關人員在製定產品組合決策、優先考慮臨床開發以及製定商業化策略時應考慮的臨床背景和策略因素。

透過科學突破、患者期望和醫療保健服務模式的改變，一股變革力量正在重塑陰道炎治療的前景。

陰道炎治療領域正經歷著一場變革，這場變革是由科學、商業性和病患主導等多面向因素共同推動的。微生物組學和標靶抗真菌藥物的科學進步正在拓展治療選擇，並使研發人員能夠從通用產品轉向針對特定病因和復發因素的干涉措施。

本報告預測了 2025 年美國關稅措施對陰道炎治療的供應鏈、價格趨勢和臨床可及性的累積影響。

主要經濟體實施的關稅措施將對藥品的採購、生產和分銷產生連鎖反應，預計美國將在2025年進行政策調整，這將要求陰道炎治療的整個價值鏈進行周密的戰略規劃。進口關稅的變化，無論是針對原料、成品或包裝材料，都會影響採購決策、與供應商的談判、生產基地的地理位置。為因應這種情況，企業應預估供應商集中度的變化，並考慮採用雙重採購策略，以降低對單一國家供應商的依賴風險。

可操作的細分訊息，包括治療領域、給藥途徑、產品類型、分銷管道和人口統計群體，這些資訊可驅動臨床和商業決策。

有效的細分對於陰道炎治療的商業性和臨床策略至關重要，因為它能明確臨床差異和商業性機會的交會點。治療方法區分了抗真菌療法和益生菌療法。在抗黴菌療法中，又可分為Azole和Polyenes；Azole可細分為Clotrimazole、Fluconazole和Miconazole等主要藥物，而Polyenes則包括Amphotericin B和製黴菌素。這種細分至關重要，因為不同類別藥物的治療方法、復發情況和抗藥性均存在差異，從而影響臨床動態和實證醫學證據的需求。

美洲、歐洲、中東和非洲以及亞太地區的戰略展望，決定市場進入和供應優先事項。

區域趨勢對陰道炎治療的整體情況產生顯著影響，包括監管環境、供應鏈物流和病患就醫策略。美洲地區擁有多元化的支付方體系和分銷模式，公私採購機制並存，且數位化醫療的普及率穩步提升，因此，那些臨床療效顯著且能遵守用藥的產品更受青睞，而那些能夠有效利用機構採購和零售/線上通路的製造商也將獲得豐厚回報。

在不斷發展的陰道炎治療生態系統中，製造商、創新者和經銷商面臨的競爭力和業務挑戰。

如今，陰道炎治療市場的競爭優勢取決於臨床差異化、配方創新和分銷彈性的綜合運用。擁有豐富產品系列的成熟製造商通常利用規模經濟來確保產品在銷售管道的充足供應和快速補貨，而規模小規模的創新型公司則通常在臨床差異化、新型作用機製或更優的耐受性方面展開競爭。企業面臨的策略挑戰包括：投資於強力的比較研究，以證明其產品能夠降低復發率並顯著改善病患報告結局（PRO）；以及開發有助於提高用藥依從性和保護消費者隱私的包裝和給藥形式。

為陰道炎治療產業的領導者提供極具影響力的策略建議，以改善患者治療效果、最佳化產品組合併確保具有韌性的供應鏈。

產業領導者應在臨床、商業和營運領域採取一系列以行動為導向、注重實施的步驟，將洞見轉化為可衡量的成果。優先開發能夠產生直接比較的臨床結果和復發數據的途徑至關重要，因為這些終點指標對支付者和臨床醫生的決策影響日益顯著。臨床計畫必須輔以以病人為中心的證據，並利用這些證據來提案其價值，這些證據應涵蓋用藥依從性、生活品質 (QOL) 指標以及真實世界中的複發預防情況。

對穩健的調查方法進行概述，說明基礎資料來源、分析架構、檢驗過程和治療分析的限制。

本報告的研究基於三角測量法，該方法結合了對關鍵相關人員的訪談、對同行評審臨床文獻的系統性回顧、對監管指南的分析以及對分銷和供應鏈指標的評估。主要資料來源包括對臨床醫生、處方集經理、採購經理和產品開發專家的結構化訪談，以獲取關於臨床需求、證據預期和獲取挑戰的第一手觀點。次要分析整合了臨床試驗結果、指引更新和安全性概況，以確保臨床結論是基於已發表的證據。

整合策略洞察和整體視角，將臨床、監管和商業性知識轉化為相關人員可採取的優先事項。

本報告的總結展望部分整合了臨床、監管和商業性的見解，為參與陰道炎治療的相關人員提出了一系列一致的優先事項。無論療法的分類或給藥途徑如何，需求都很明確：能夠顯著降低復發率、提高耐受性和患者偏好的治療方法最有可能獲得持續推廣。這需要一種綜合方法，結合嚴謹的臨床試驗、真實世界數據 (RWE) 收集和數位化互動策略，以支持患者的用藥依從性和監測。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 依治療方法分類的陰道炎治療市場

  • 抗真菌治療
    • Azole
      • Clotrimazole
      • Fluconazole
      • Miconazole
    • Polyenes
      • Amphotericin B
      • 制黴菌素
  • 益生菌療法

第9章 陰道炎治療市場：依產品類型分類

  • 非處方藥
  • 處方藥

第10章 陰道炎治療市場：依給藥途徑分類

  • 陰道內部
    • 奶油
    • 凝膠
    • 栓劑
  • 口服
    • 膠囊
    • 藥片
  • 外用
    • 奶油
    • 凝膠
    • 軟膏

第11章 陰道炎治療市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章：按最終用戶細分的陰道炎治療市場

  • 停經後婦女
    • 46-60歲
    • 60歲或以上
  • 閉經婦女
    • 18-25歲
    • 26-35歲
    • 36-45歲
  • 孕婦

第13章 陰道炎治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 陰道炎治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 陰道炎治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國陰道炎治療市場

第17章：中國陰道炎治療市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Bayer Aktiengesellschaft
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Glenmark Pharmaceuticals Ltd.
  • Lupin Limited
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • The Procter & Gamble Company
  • Viatris Inc.
Product Code: MRR-8E22B61932BA

The Vaginitis Therapeutics Market was valued at USD 3.00 billion in 2025 and is projected to grow to USD 3.26 billion in 2026, with a CAGR of 9.55%, reaching USD 5.69 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.00 billion
Estimated Year [2026] USD 3.26 billion
Forecast Year [2032] USD 5.69 billion
CAGR (%) 9.55%

A concise yet compelling overview of vaginitis therapeutics that frames urgency, clinical unmet needs, and strategic priorities for stakeholders

Vaginitis remains a focal point for clinicians, payers, and product developers because it intersects prevalent clinical need, diagnostic complexity, and a shifting patient preference landscape. The introduction below frames the clinical context and strategic drivers that should inform portfolio decisions, clinical development prioritization, and commercialization strategies for stakeholders across healthcare and life sciences.

Clinically, vaginitis encompasses a spectrum of etiologies that demand divergent therapeutic approaches, ranging from antifungal regimens to probiotic adjuncts aimed at restoring microbiome balance. Diagnostic ambiguity persists in many care pathways, complicating treatment selection and driving patient dissatisfaction. At the same time, advancements in formulation science and increasing acceptance of at-home care pathways have expanded the tactical options available to manufacturers and providers. These trends create both opportunities for differentiated product positioning and risks for commoditization if clinical value is not clearly articulated.

From a strategic perspective, the convergence of regulatory scrutiny, payer emphasis on cost-effectiveness, and digital health enablement is reshaping how therapies progress from concept to clinic. Commercial strategies must therefore integrate clinical evidence generation, real-world outcomes capture, and patient-centric access models to build sustainable adoption. In short, the field calls for an integrated approach that aligns therapeutic innovation with pragmatic deployment in diverse care settings.

Evolutionary forces reshaping the vaginitis treatment landscape through scientific breakthroughs, patient expectations, and shifts in care delivery models

The landscape for vaginitis therapeutics is undergoing transformative shifts driven by converging scientific, commercial, and patient-driven forces. Scientific advances in microbiome science and targeted antifungal pharmacology are broadening the therapeutic toolkit, enabling developers to move beyond one-size-fits-all products toward interventions that address specific etiologies and recurrence drivers.

Concurrently, patients are exerting greater influence over care choices, favoring discreet, convenient, and evidence-backed options that fit into their daily routines. This has accelerated demand for oral and intravaginal formats that deliver rapid symptom relief while fitting home-based treatment paradigms. Digital diagnostics and telehealth are also reshaping early triage and treatment initiation, reducing barriers to care but raising expectations for integrated digital support and clear evidence of clinical benefit.

Commercial dynamics are evolving in parallel: payers and procurement stakeholders increasingly prioritize therapeutic value demonstrated through outcomes and reduced recurrence rates. Manufacturers that invest in robust post-market evidence, adherence support initiatives, and supply chain resilience will be better positioned to secure formulary access and provider endorsement. Taken together, these shifts signal a market that rewards targeted clinical differentiation, patient-centric delivery models, and data-driven value propositions.

Anticipating the cumulative implications of United States tariff actions in 2025 on supply chains, pricing dynamics, and clinical accessibility across vaginitis therapeutics

Tariff actions originating from major economies can have cascading effects across pharmaceutical sourcing, manufacturing, and distribution, and the United States policy adjustments anticipated in 2025 warrant careful strategic planning across the vaginitis therapeutics value chain. Changes in import duties, whether enacted on raw materials, finished dosage forms, or packaging components, can influence procurement decisions, supplier negotiations, and the geographic configuration of production footprints. In response, organizations should anticipate shifts in supplier concentration and consider dual-sourcing strategies to mitigate single-country exposure.

Price pressure may manifest differently across segments; products that are predominantly imported or rely on complex supply chains could see cost passthrough pressures that affect list prices, payer negotiations, and ultimately patient out-of-pocket costs. Moreover, tariff-induced cost variability can compress margins for commoditized therapeutics unless manufacturers proactively redesign supply chains, optimize formulation yields, or transition certain components to domestic production. Regulatory timelines and batch release processes must also be recalibrated when manufacturing relocations occur to prevent interruptions in product availability.

Beyond direct cost implications, tariffs can catalyze strategic responses such as increased vertical integration, regional manufacturing hubs, and greater emphasis on supplier partnerships that lock in long-term pricing and capacity. Stakeholders should therefore adopt scenario-based planning, stress-test procurement and distribution assumptions, and prioritize investments that enhance agility, cost visibility, and continuity of supply to reduce exposure to trade policy volatility.

Actionable segmentation intelligence on therapeutic classes, routes, product types, distribution channels, and demographic cohorts driving clinical and commercial decisions

Effective segmentation is foundational to commercial and clinical strategy in vaginitis therapeutics because it clarifies where clinical differentiation and commercial opportunities converge. Treatment type segmentation distinguishes antifungal therapies from probiotic approaches; within antifungal treatments there are class distinctions between azoles and polyenes, with azoles further segmented by dominant agents such as clotrimazole, fluconazole, and miconazole, while polyenes encompass amphotericin B and nystatin. This therapeutic granularity matters because pharmacodynamics, recurrence profiles, and resistance considerations differ across classes, shaping clinical positioning and evidence generation needs.

Route of administration is another pivotal segmentation axis. Intravaginal delivery subdivides into creams, gels, and suppositories, each offering distinct onset-of-action profiles, adherence implications, and patient preferences. Oral formulations are categorized into capsules and tablets, which present advantages in terms of systemic exposure and convenience but require different safety and labeling considerations. Topical preparations, including creams, gels, and ointments, serve unique roles in symptomatic relief and localized therapy and are evaluated differently by providers and patients.

Product type division between over-the-counter and prescription status impacts promotional approaches, regulatory obligations, and access pathways. Distribution channel segmentation spans hospital pharmacies, online pharmacies, and retail pharmacies, each with unique purchasing behaviors, formulary dynamics, and service expectations. Finally, end user demographic segmentation differentiates post-menopausal women, pre-menopausal women, and pregnant women; these cohorts are further stratified by age bands that influence prevalence, comorbidity profiles, and tolerability concerns. Integrating these segmentation dimensions enables stakeholders to design targeted clinical trials, tailor messaging to specific care settings, and prioritize channels that optimize adoption and adherence.

Regionally differentiated strategic outlooks for the Americas, Europe Middle East and Africa, and Asia-Pacific that inform market access and supply priorities

Regional dynamics exert a profound influence on regulatory pathways, supply logistics, and patient access strategies across the vaginitis therapeutics landscape. The Americas region combines diverse payer systems and distribution models, where private and public procurement mechanisms coexist and where digital care adoption is steadily increasing. These dynamics favor products that demonstrate a clear clinical differentiator or improved adherence, and they reward manufacturers that can navigate both institutional purchasing and retail/online channels.

In Europe, Middle East & Africa, heterogeneity in regulatory frameworks and reimbursement pathways requires adaptive market entry playbooks. Some markets demand extensive clinical comparators and health economics evidence, while others prioritize cost-effective, easily deployable solutions. Supply chain complexity and variable cold chain infrastructures in certain geographies also influence product design and packaging decisions. In contrast, the Asia-Pacific region is characterized by rapid adoption of digital health platforms, high-volume demand for both prescription and over-the-counter solutions, and growing local manufacturing capacity. These attributes create opportunities for scalable, low-cost formulations as well as differentiated specialty products targeted at urban centers and digitally enabled patient segments.

Across all regions, local epidemiology, cultural perceptions of women's health, and access to primary care shape uptake. Consequently, regional strategies should align regulatory engagement, distribution partnerships, and patient education initiatives with local healthcare delivery realities to maximize clinical impact and commercial viability.

Competitive dynamics and corporate imperatives for manufacturers, innovators, and distributors competing in the evolving vaginitis therapeutics ecosystem

Competitive positioning in vaginitis therapeutics now hinges on a blend of clinical differentiation, formulation innovation, and distribution agility. Incumbent manufacturers that maintain broad product portfolios often leverage scale to secure channel placement and rapid replenishment, while smaller innovators typically compete on clinical differentiation, novel mechanisms, or superior tolerability profiles. Strategic imperatives for companies include investing in robust comparative evidence that demonstrates reduced recurrence and meaningful patient-reported outcomes, as well as developing packaging and delivery formats that enhance adherence and consumer discretion.

Collaboration between pharmaceutical developers and digital health firms has emerged as an important axis of competitive advantage, enabling bundled offerings that combine pharmacologic therapy with adherence support, symptom tracking, and remote clinician engagement. Moreover, companies that align product development with regulatory pathways for label expansion or OTC switches can unlock new access channels and broaden patient reach. Operationally, securing resilient manufacturing partnerships and flexible contract manufacturing agreements mitigates risk from supply interruptions and tariff-related cost shifts.

Mergers, licensing deals, and strategic alliances remain viable routes to accelerate capability acquisition, whether that entails gaining access to novel probiotic strains, advanced intravaginal delivery platforms, or regional distribution networks. Ultimately, successful companies will integrate clinical excellence with commercial finesse and operational resilience to navigate a competitive and policy-sensitive environment.

High-impact strategic recommendations for industry leaders to accelerate patient outcomes, optimize portfolios, and secure resilient supply chains in vaginitis care

Industry leaders should adopt a set of pragmatic, implementation-focused actions to translate insights into measurable outcomes across clinical, commercial, and operational domains. First, prioritize development pathways that generate head-to-head clinical outcomes and recurrence data, as these endpoints increasingly drive payer and clinician decision-making. Complement clinical programs with patient-centered evidence that captures adherence, quality-of-life metrics, and real-world recurrence prevention to strengthen value propositions.

Second, optimize product portfolios by aligning formulation choices with care settings and patient preferences; for example, invest in discreet intravaginal formats for home treatment, and ensure oral options are supported by clear safety profiles that enable wider primary care adoption. Third, build supply chain resilience through geographic diversification of manufacturing, strategic supplier contracting, and inventory strategies that accommodate tariff volatility and regional demand fluctuations. Fourth, accelerate digital integration by coupling therapies with telehealth-compatible diagnostics and adherence tools, thereby creating stickier patient journeys and enhancing clinical follow-up.

Finally, advance commercial readiness by tailoring distribution strategies across hospital pharmacies, retail points, and online pharmacies, and by developing payer engagement plans that foreground outcomes and economic case narratives. Executed together, these recommendations will help organizations convert scientific and commercial potential into durable clinical impact and market differentiation.

Robust research methodology overview describing data sources, analytical frameworks, validation processes, and limitations underpinning the therapeutic analysis

The research underpinning this report relies on a triangulated methodology that combines primary stakeholder interviews, systematic review of peer-reviewed clinical literature, analysis of regulatory guidelines, and evaluation of distribution and supply chain indicators. Primary inputs include structured interviews with clinicians, formulary managers, procurement leads, and product development experts to capture firsthand perspectives on clinical needs, evidence expectations, and access challenges. Secondary analyses synthesize clinical trial results, guideline updates, and safety profiles to ensure clinical assertions are grounded in the published evidence base.

Data on distribution practices and manufacturing configurations are derived from a combination of public regulatory filings, supply chain disclosures, and industry reports to map typical logistics flows and identify vulnerability points. Analytical frameworks incorporate scenario analysis to evaluate resilience under different trade and policy conditions, as well as cross-segmentation mapping to align product archetypes with distribution channels and end-user cohorts. Validation steps include peer review by subject-matter experts and consistency checks across independent data sources to minimize bias.

Limitations are acknowledged where primary data are constrained or where heterogeneity across regions inhibits universal conclusions. Where appropriate, recommendations are couched in conditional terms and accompanied by suggested next steps for further targeted evidence generation or in-market validation.

Synthesis of strategic insights and closing perspectives that translate clinical, regulatory, and commercial intelligence into executable priorities for stakeholders

The concluding perspective synthesizes clinical, regulatory, and commercial insights into a coherent set of priorities for stakeholders invested in vaginitis therapeutics. Across therapeutic classes and routes of administration, the imperative is clear: therapies that demonstrate meaningful reductions in recurrence, improved tolerability, and alignment with patient preferences are most likely to achieve durable adoption. Implementing this requires an integrated approach that pairs rigorous clinical programs with real-world evidence collection and digital engagement strategies to support adherence and monitoring.

Operational resilience is equally essential; organizations must address supply chain fragility and tariff exposure through diversified sourcing, regional manufacturing options, and strategic inventory management. Commercially, segmentation-informed go-to-market strategies that consider route of administration, product type, distribution channel, and end-user demographics will sharpen targeting and reduce commercial waste. Finally, collaboration across industry, clinical societies, and payer stakeholders can accelerate development of standardized diagnostics and care pathways that benefit patients and streamline adoption.

Taken together, these priorities form a roadmap for translating scientific advances into tangible improvements in patient outcomes while preserving commercial viability in a complex and rapidly evolving environment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Vaginitis Therapeutics Market, by Treatment Type

  • 8.1. Antifungal Treatments
    • 8.1.1. Azoles
      • 8.1.1.1. Clotrimazole
      • 8.1.1.2. Fluconazole
      • 8.1.1.3. Miconazole
    • 8.1.2. Polyenes
      • 8.1.2.1. Amphotericin B
      • 8.1.2.2. Nystatin
  • 8.2. Probiotic Treatments

9. Vaginitis Therapeutics Market, by Product Type

  • 9.1. Over The Counter
  • 9.2. Prescription

10. Vaginitis Therapeutics Market, by Route Of Administration

  • 10.1. Intravaginal
    • 10.1.1. Creams
    • 10.1.2. Gels
    • 10.1.3. Suppositories
  • 10.2. Oral
    • 10.2.1. Capsules
    • 10.2.2. Tablets
  • 10.3. Topical
    • 10.3.1. Creams
    • 10.3.2. Gels
    • 10.3.3. Ointments

11. Vaginitis Therapeutics Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies

12. Vaginitis Therapeutics Market, by End User Demographics

  • 12.1. Post-Menopausal Women
    • 12.1.1. Age 46-60
    • 12.1.2. Age 60+
  • 12.2. Pre-Menopausal Women
    • 12.2.1. Age 18-25
    • 12.2.2. Age 26-35
    • 12.2.3. Age 36-45
  • 12.3. Pregnant Women

13. Vaginitis Therapeutics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Vaginitis Therapeutics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Vaginitis Therapeutics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Vaginitis Therapeutics Market

17. China Vaginitis Therapeutics Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Bayer Aktiengesellschaft
  • 18.6. Cipla Limited
  • 18.7. Dr. Reddy's Laboratories Ltd.
  • 18.8. Glenmark Pharmaceuticals Ltd.
  • 18.9. Lupin Limited
  • 18.10. Pfizer Inc.
  • 18.11. Sun Pharmaceutical Industries Limited
  • 18.12. Teva Pharmaceutical Industries Ltd.
  • 18.13. The Procter & Gamble Company
  • 18.14. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL VAGINITIS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL VAGINITIS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA VAGINITIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CLOTRIMAZOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CLOTRIMAZOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CLOTRIMAZOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY FLUCONAZOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY FLUCONAZOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY FLUCONAZOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY MICONAZOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY MICONAZOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY MICONAZOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AMPHOTERICIN B, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AMPHOTERICIN B, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AMPHOTERICIN B, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY NYSTATIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY NYSTATIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY NYSTATIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PROBIOTIC TREATMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PROBIOTIC TREATMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PROBIOTIC TREATMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY OVER THE COUNTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY OVER THE COUNTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY OVER THE COUNTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRESCRIPTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRESCRIPTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRESCRIPTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CREAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CREAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CREAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY GELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY GELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY GELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY SUPPOSITORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY SUPPOSITORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY SUPPOSITORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CREAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CREAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CREAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY GELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY GELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY GELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY OINTMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY OINTMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 46-60, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 46-60, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 46-60, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 60+, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 60+, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 60+, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 18-25, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 18-25, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 18-25, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 26-35, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 26-35, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 26-35, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 36-45, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 36-45, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 36-45, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PREGNANT WOMEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PREGNANT WOMEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PREGNANT WOMEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2018-2032 (USD MILLION)
  • TABLE 212. AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2018-2032 (USD MILLION)
  • TABLE 221. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 224. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2018-2032 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2018-2032 (USD MILLION)
  • TABLE 227. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2018-2032 (USD MILLION)
  • TABLE 236. ASEAN VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 237. ASEAN VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 238. ASEAN VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 239. ASEAN VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 240. ASEAN VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2018-2032 (USD MILLION)
  • TABLE 241. ASEAN VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2018-2032 (USD MILLION)
  • TABLE 242. GCC VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 243. GCC VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. GCC VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 245. GCC VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 246. GCC VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 247. GCC VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. GCC VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 249. GCC VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2018-2032 (USD MILLION)
  • TABLE 250. GCC VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 251. GCC VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 252. GCC VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 253. GCC VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 254. GCC VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2018-2032 (USD MILLION)
  • TABLE 255. GCC VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPEAN UNION VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPEAN UNION VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPEAN UNION VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPEAN UNION VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPEAN UNION VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPEAN UNION VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2018-2032 (USD MILLION)
  • TABLE 270. BRICS VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 271. BRICS VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. BRICS VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 273. BRICS VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 274. BRICS VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 275. BRICS VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. BRICS VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 277. BRICS VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2018-2032 (USD MILLION)
  • TABLE 278. BRICS VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 279. BRICS VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 280. BRICS VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 281. BRICS VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 282. BRICS VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2018-2032 (USD MILLION)
  • TABLE 283. BRICS VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2018-2032 (USD MILLION)
  • TABLE 284. G7 VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 285. G7 VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 286. G7 VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 287. G7 VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 288. G7 VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 289. G7 VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 290. G7 VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 291. G7 VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2018-2032 (USD MILLION)
  • TABLE 292. G7 VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 293. G7 VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 294. G7 VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 295. G7 VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 296. G7 VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2018-2032 (USD MILLION)
  • TABLE 297. G7 VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2018-2032 (USD MILLION)
  • TABLE 298. NATO VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 299. NATO VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 300. NATO VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 301. NATO VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 302. NATO VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 303. NATO VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 304. NATO VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 305. NATO VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2018-2032 (USD MILLION)
  • TABLE 306. NATO VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 307. NATO VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 308. NATO VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 309. NATO VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 310. NATO VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2018-2032 (USD MILLION)
  • TABLE 311. NATO VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2018-2032 (USD MILLION)
  • TABLE 312. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 313. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 314. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 315. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 316. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 317. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 318. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 319. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 320. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2018-2032 (USD MILLION)
  • TABLE 321. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 322. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 323. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 324. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DE